PreveCeutical Medical Inc (18H) - Total Liabilities
Based on the latest financial reports, PreveCeutical Medical Inc (18H) has total liabilities worth €7.85 Million EUR as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
PreveCeutical Medical Inc - Total Liabilities Trend (2016–2024)
This chart illustrates how PreveCeutical Medical Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
PreveCeutical Medical Inc Competitors by Total Liabilities
The table below lists competitors of PreveCeutical Medical Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Cosmo Metals Ltd
AU:CMO
|
Australia | AU$645.80K |
|
Resource Base Ltd
AU:RBX
|
Australia | AU$136.94K |
|
Kaushalya Infrastructure Development Corporation Limited
NSE:KAUSHALYA
|
India | Rs18.06 Million |
|
Comanche International Public Company Limited
BK:COMAN
|
Thailand | ฿14.00 Million |
|
Golden State Mining Ltd
AU:GSM
|
Australia | AU$416.04K |
|
Weaccess Group SA
PA:MLWEA
|
France | €1.16 Million |
|
On The Beach Group PLC
LSE:OTB
|
UK | GBX345.30 Million |
|
Bubalus Resources Ltd
AU:BUS
|
Australia | AU$122.42K |
Liability Composition Analysis (2016–2024)
This chart breaks down PreveCeutical Medical Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.04 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.05 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 17.21 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how PreveCeutical Medical Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for PreveCeutical Medical Inc (2016–2024)
The table below shows the annual total liabilities of PreveCeutical Medical Inc from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €6.86 Million | +15.15% |
| 2023-12-31 | €5.96 Million | +23.54% |
| 2022-12-31 | €4.82 Million | +13.11% |
| 2021-12-31 | €4.27 Million | +9.19% |
| 2020-12-31 | €3.91 Million | -26.91% |
| 2019-12-31 | €5.34 Million | +27.64% |
| 2018-12-31 | €4.19 Million | +42.23% |
| 2017-12-31 | €2.94 Million | +485.00% |
| 2016-12-31 | €503.24K | -- |
About PreveCeutical Medical Inc
PreveCeutical Medical Inc., a health sciences company, engages in the development of options for preventive and curative therapies utilizing organic and nature identical products. Its pipeline products include Cannabinoid Sol-Gel Delivery, a cannabinoid-based nose-to-brain delivery system that provides relief from various indications, including pain, inflammation, seizures, and neurological disor… Read more